MEXITIL Drug Patent Profile
✉ Email this page to a colleague
When do Mexitil patents expire, and what generic alternatives are available?
Mexitil is a drug marketed by Boehringer Ingelheim and is included in one NDA.
The generic ingredient in MEXITIL is mexiletine hydrochloride. There are five drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the mexiletine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mexitil
A generic version of MEXITIL was approved as mexiletine hydrochloride by TEVA on May 16th, 1995.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MEXITIL?
- What are the global sales for MEXITIL?
- What is Average Wholesale Price for MEXITIL?
Summary for MEXITIL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 214 |
| Clinical Trials: | 4 |
| Patent Applications: | 4,141 |
| DailyMed Link: | MEXITIL at DailyMed |
Recent Clinical Trials for MEXITIL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Massachusetts General Hospital | Phase 2 |
| Food and Drug Administration (FDA) | Phase 1 |
| Spaulding Clinical Research LLC | Phase 1 |
US Patents and Regulatory Information for MEXITIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | MEXITIL | mexiletine hydrochloride | CAPSULE;ORAL | 018873-002 | Dec 30, 1985 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Boehringer Ingelheim | MEXITIL | mexiletine hydrochloride | CAPSULE;ORAL | 018873-003 | Dec 30, 1985 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Boehringer Ingelheim | MEXITIL | mexiletine hydrochloride | CAPSULE;ORAL | 018873-004 | Dec 30, 1985 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MEXITIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | MEXITIL | mexiletine hydrochloride | CAPSULE;ORAL | 018873-002 | Dec 30, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Boehringer Ingelheim | MEXITIL | mexiletine hydrochloride | CAPSULE;ORAL | 018873-003 | Dec 30, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Boehringer Ingelheim | MEXITIL | mexiletine hydrochloride | CAPSULE;ORAL | 018873-004 | Dec 30, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Boehringer Ingelheim | MEXITIL | mexiletine hydrochloride | CAPSULE;ORAL | 018873-004 | Dec 30, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Boehringer Ingelheim | MEXITIL | mexiletine hydrochloride | CAPSULE;ORAL | 018873-003 | Dec 30, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Boehringer Ingelheim | MEXITIL | mexiletine hydrochloride | CAPSULE;ORAL | 018873-002 | Dec 30, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MEXITIL
See the table below for patents covering MEXITIL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 1643240 | ⤷ Sign Up | |
| Italy | 7949431 | ⤷ Sign Up | |
| Switzerland | 509250 | Verfahren zur Herstellung neuer substituierter 1-Phenoxy-2-aminopropane (1-Phenoxy-2-aminoalkanes) | ⤷ Sign Up |
| United Kingdom | 1205958 | ⤷ Sign Up | |
| France | 7521 | ⤷ Sign Up | |
| Germany | 1543369 | 1-ARYLOXY-2-AMINOALKANE UND PHARMAZEUTISCHE PRAEPARATE AUF DEREN BASIS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
